Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biosecurity

    Soligenix, Emergent BioSolutions Announce Ricin Vaccine Agreement

    By Global Biodefense StaffMay 14, 2015
    Ricin Vaccine Research
    Share
    Facebook LinkedIn Reddit Email

    Soligenix, Inc. this week announced that it has initiated a development agreement with Emergent BioSolutions to implement a commercially viable, scalable production technology for the RiVax drug substance protein antigen.

    RiVax is a vaccine candidate being developed to protect against ricin exposure.  Soligenix will transfer the manufacturing processes and analytics to Emergent to conduct process development work that could potentially lead to a future commercial manufacturing collaboration.

    Soligenix has been developing RiVax, in conjunction with its heat stabilization technology, ThermoVax, as a heat-stable biodefense vaccine.  RiVax has demonstrated both 100% protection in a preclinical model of lethal ricin exposure and stability up to 1 year at 40 degrees Celsius facilitating storage at ambient temperature.  RiVax is being developed as a safe and effective biodefense vaccine which does not require cold chain shipment and storage.

    “We are pleased to initiate an agreement with Emergent BioSolutions as we expand our efforts to develop an effective, first-in-class vaccine against ricin toxin exposure in combination with our thermostabilization technology,” stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix.  “Collaborating with NIAID and Emergent is an important step in advancing the development of our ThermoVax™ technology platform. Soligenix intends to use this innovative technology to develop a heat stable ricin toxin vaccine that meets US Government requirements and advances a vaccine thermostabilization platform that may apply to other vaccines.”

    The RiVax project has been funded with Federal funds from the National Institute of Allergy and Infectious Diseases (NIAID).  The agreement between Soligenix and Emergent is specifically funded by NIAID under Contract No. HHSN272201400039C.

    NIAID Ricin Vaccine News
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleFunding for Food Protection Rapid Response Teams
    Next Article RFI – Chemical Agent Countermeasure Support

    Related Stories

    Committee to Examine Transmission and Geographic Spread of Chronic Wasting Disease

    September 24, 2023

    New Method Improves Quantification of Ricin in Complex Matrices

    September 20, 2023

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    Mount Sinai to Lead Development of Pan-Coronavirus Vaccine Under New Federal Grant

    September 17, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy